|
Market Closed -
Nasdaq
16:00:00 2026-09-08 EDT
|
5-day change | 1st Jan Change | ||
| 5.390 USD | -4.09% |
|
-10.17% | -53.73% |
| 08-13 | ARS Pharmaceuticals Q2 Net Loss Widens, Revenue Rises | MT |
| 08-13 | ARS Pharmaceuticals, Inc., Q2 2026 Earnings Call, Aug 13, 2026 |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 559M | - | - | - | ||
| 48.41B | |||||
| 45.01B | - | - | - | - | - |
| 44.07B | |||||
| 40.73B | |||||
| 33.21B |
Select your edition
All financial news and data tailored to specific country editions
